New drug targeting LF and onchocerciasis begins its first in human trial in Liverpool

A new drug developed by an LSTM led partnership, which targets the neglected tropical diseases lymphatic filariasis and onchocerciasis has begun its first in human trial.

Related Keywords

United Kingdom ,Paul Oneill ,Mark Taylor ,Emily Henderson ,Liverpool University Hospitals ,Melinda Gates Foundation ,Eisai Co ,Foundation Trust On ,Global Health Innovative Technology ,University Of Liverpool ,Department Of Chemistry ,Broadgreen Clinical Research Facility ,Professor Steve Ward ,Onchocerciasis ,Drugs ,Filariasis ,Lymphatic Filariasis ,Medicine ,Olecule ,Reclinical ,Wolbachia ,